Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

99 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-23

Study Completion Date

2024-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the efficacy of IL-37 as a biomarker to predict mortality risk in adults with sepsis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients

NCT05911711

Sepsis

UNKNOWN

Effect of Immunophenotype on Prognosis of Sepsis

NCT05602584

Sepsis Septic Shock Sepsis Syndrome

UNKNOWN

Establishment of Early Diagnosis and Monitoring Model for Sepsis Patients

NCT04974411

Sepsis

UNKNOWN

Study on the Construction and Application of Early Warning Model of Sepsis in Critically Ill Patients

NCT06904001

Sepsis Sepsis and Septic Shock Infection

ENROLLING_BY_INVITATION

Risk Factors for Adverse Outcomes in Sepsis

NCT06541600

Sepsis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sepsis patients admitted in the Department of Critical Care Medicine, Zhongnan Hospital will be included.

There are three groups of patients in this study: control group, sepsis group and septic shock group.

The interleukin-37 (IL-37) concentration in urine was analyzed in the day 1, 2, 4, 6.

Additionally, IL-37 concentration between blood stream infection groups and non-infection groups were analyzed. IL-37 concentration between survivors and non-survivors were also compared. IL-37 concentration were followed from day 1, 2, 4, 6.The correlation between the concentration of IL-37, IL-1β, IL-6、IL-10 and TNF-α were analyzed. Furthermore, the investigators will determine the correlation between the concentration of IL-37, sepsis associated organ dysfunction, 28-day mortality. Lastly, the predictive value of IL-37 to sepsis associated organ dysfunction and prognosis were explored.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18 years or older
2. Expected length of stay\>24 hours in intensive care unit (ICU)
3. Sequential organ failure assessment (SOFA) score ≥ 2 on ICU admission with a suspicion of infection